Drug-related hepatotoxicity

New England Journal of Medicine

Volumn 354, Issue 7, 2006, Pages 731-739

  Navarro, Victor J ^a,c   Senior, John R ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLCYSTEINE; ALLOPURINOL; AMFEBUTAMONE; AMIODARONE; AMITRIPTYLINE; BACLOFEN; CAPTOPRIL; CARNITINE; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; KAVA; KETOCONAZOLE; LISINOPRIL; LOSARTAN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PAROXETINE; PYRAZINAMIDE; RIFAMPICIN; RISPERIDONE; SERTRALINE; TETRACYCLINE; TRAZODONE; TROGLITAZONE; TROVAFLOXACIN; UNINDEXED DRUG; VALPROIC ACID;

DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEPATITIS E; HOSPITALIZATION; HUMAN; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 32644469104     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra052270     Document Type: Review

References (62)

1. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22:145-55.
2. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5.
3. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-97.
4. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;41:1405-9.
5. Lee WM. Drug-induced acute liver failure in the United State 2005: results from the U.S. Acute Liver Failure Study Group. FDA-PhRMA-AASLD Hepatotoxicity Steering Committee meeting 28 January 2005. (Accessed January 20, 2006, at http://www. fda.gov/cder/livertox/presentations2005/William_Lee.ppt.)
6. Temple RJ. Hepatotoxicity through the years: impact on the FDA. (Accessed January 20, 2006, at http://www.fda.gov/cder/livertox/Presentations/im1389/ sld001.htm.)
7. Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11:272-6.
8. FDA Working Group. CDER-PhRMA-AASLD Conference 2000: clinical white paper on drug-induced hepatotoxicity, November 2000. (Accessed January 20, 2006, at http://www.fda.gov/cder/livertox/clinical. pdf.)
9. Rosalski SB, McIntyre N. Biochemical investigations in the management of liver disease. In: Bircher J, Benhamou J-P, McIntyre N, Rizetto M, Rodes J, eds. Oxford handbook of clinical hepatology. 2nd ed. Oxford, England: Oxford University Press, 1999:504.
10. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts, 1978.
11. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-9.
12. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21.
13. [Erratum, Gastroenterology 2005;129:1808.]
14. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associate with isoniazid preventative therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.
15. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
16. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38:Suppl 2:S44-S48.
17. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-91.
18. Beaune P, Dansette PM, Mansuy D, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A 1987;84:551-5.
19. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997;26:Suppl 1:23-30.
20. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
21. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993;21:403-9.
22. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998;339:1217-27.
23. Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 2001;7:314-9.
24. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69.
25. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
26. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002;22:137-44.
27. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
28. Prescott LF, Critchley JA. The treatment of acetaminophen poisoning. Annu Rev Pharmacol Toxicol 1983;23:87-101.
29. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;272:1845-50.
30. Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology 2004;126:1477-9.
31. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997;26:Suppl 2:12-21.
32. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
33. Huang Y-S, Chern H-D, Su W-J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-9.
34. Lankisch TO, Vogel A, Eilermann S, et al. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 2005;67:1732-9.
35. Mehra R, Murren J, Chung G, Smith B, Psyrri A. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism. Clin Colorectal Cancer 2005;5:61-4.
36. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
37. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000;45:1929-34.
38. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
39. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248-50.
40. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92.
41. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-10.
42. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
43. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6.
44. Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004;3:329-44.
45. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-9.
46. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-30.
47. Lee WM, Senior JR. Recognizing druginduced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155-64.
48. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26:Suppl 1:31-5.
49. Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992;15:244-51.
50. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80.
51. The binomial distribution. In: Rosner B. Fundamentals of biostatistics. Belmont, Calif.: Duxbury Press, 1995:82-5.
52. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916-7.
53. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306.
54. Watkins PB. Insight into hepatotoxicity: the troglitazone experience. Hepatology 2005;41:229-30.
55. Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269:2765-8.
56. Ahmad SR. MEDWatch. Lancet 1993;341:1465-6.
57. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med 2001;134:330-4.
58. Arnaiz JA, Carné X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001;57:89-91.
59. Ray WA. Population-based studies of adverse drug effects. N Engl J Med 2003;349:1592-4.
60. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
61. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42:1364-72.
62. Hoofnagle JH. Drug-Induced Liver Injury Network (DILIN). Hepatology 2004;40:773.